<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176642</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00052742</org_study_id>
    <nct_id>NCT02176642</nct_id>
  </id_info>
  <brief_title>Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.</brief_title>
  <acronym>APP</acronym>
  <official_title>Double-Blind Randomized Controlled Trial of Extended Release Oxybutynin Versus Placebo in Women Receiving Posterior Tibial Nerve Stimulation for Treatment of Urgency Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Urodynamics and Female Pelvic Medicine &amp; Urogenital Reconstruction</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo-controlled clinical trial of posterior tibial
      nerve stimulation (PTNS) plus extended release oxybutynin versus PTNS alone (placebo pills)
      in women undergoing treatment of urgency urinary incontinence (UUI).

      The investigators hypothesize that combination therapy with PTNS and anticholinergic
      medication will result in a significant incremental improvement in UUI symptoms over that
      achieved with PTNS alone. In addition, the investigators hypothesize that the addition of
      anticholinergics to PTNS will result in a greater improvement in patients' perception of
      treatment response, symptom distress, and quality of life than PTNS alone.

      Specific Aim 1: To compare the change, from baseline, in mean number of UUI episodes per day
      using a 3-day bladder diary between PTNS plus anticholinergic medication versus PTNS plus
      placebo in women undergoing treatment for UUI.

      Specific Aim 2: To compare the change, from baseline, in a 24hr pad weight between PTNS plus
      anticholinergic medication versus PTNS plus placebo.

      Specific Aim 3: To compare subjective treatment response, symptoms distress, and quality of
      life between PTNS plus anticholinergic medication versus PTNS plus placebo utilizing the
      Patient Global Impression of Improvement (PGI-I) and the Overactive Bladder Questionnaire
      Short Form (OABq-SF).

      An interim analysis will be conducted by an independent entity after 50 participants have
      completed the study protocol. A Data Safety Monitoring Board is not utilized because the
      study utilizes FDA approved treatments for urgency urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 21, 2016</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean number of UUI episodes per day</measure>
    <time_frame>6 weeks</time_frame>
    <description>To compare the change, from baseline, in mean number of UUI episodes per day using a 3-day bladder diary between PTNS plus anticholinergic medication versus PTNS plus placebo in women undergoing treatment for UUI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24hr pad weight</measure>
    <time_frame>6 weeks</time_frame>
    <description>To compare the change, from baseline, in a 24hr pad weight between PTNS plus anticholinergic medication versus PTNS plus placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in symptoms distress and quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>To compare subjective treatment response, symptoms distress, and quality of life between PTNS plus anticholinergic medication versus PTNS plus placebo utilizing the Patient Global Impression of Improvement (PGI-I), the Overactive Bladder Questionnaire Short Form (OABq-SF), the Urinary Distress Inventory (UDI-6), and the Incontinence Impact Questionnaire (IIQ-7).</description>
  </other_outcome>
  <other_outcome>
    <measure>Assess side effects</measure>
    <time_frame>6 weeks</time_frame>
    <description>To compare subjective side effects between between PTNS plus anticholinergic medication versus PTNS plus placebo using the Treatment Satisfaction Questionnaire for Medication, version two (TSQMvII) and a questionnaire assessing PTNS side effects.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Urinary Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Oxybutynin plus PTNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus PTNS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin extended release</intervention_name>
    <description>5mg tablet taken by mouth daily for 6 weeks</description>
    <arm_group_label>Oxybutynin plus PTNS</arm_group_label>
    <other_name>Ditropan XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Posterior Tibial Nerve Stimulation</intervention_name>
    <description>In office therapy administered for 30 minutes once every week for a total of 6 weeks</description>
    <arm_group_label>Oxybutynin plus PTNS</arm_group_label>
    <arm_group_label>Placebo plus PTNS</arm_group_label>
    <other_name>Urgent PC Neuromodulation system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet taken by mouth daily for 6 weeks</description>
    <arm_group_label>Placebo plus PTNS</arm_group_label>
    <other_name>Dextrose powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients

          -  &gt; 18 years of age

          -  &gt; 3 UUI episodes on a 3-day bladder diary

          -  Urge predominant ( &gt; 50% of total incontinence episodes) urinary incontinence based
             on a three-day bladder diary

          -  Existing insurance coverage of PTNS therapy.

          -  Ability to undergo weekly PTNS treatments in clinic for 6 week period of time and
             complete all study related items

          -  Not on an anticholinergic or beta agonist medication or, if they are, willing to
             undergone a three week washout period prior to randomization

        Exclusion Criteria:

          -  Any previous PTNS therapy, intra-detrusor botulinum toxin injections, or implanted
             sacral neuromodulation

          -  Contraindication to anticholinergic therapy (narrow-angle glaucoma or gastric
             retention) or PTNS therapy (implanted pacemaker/defibrillator or peripheral
             neuropathy)

          -  Symptomatic urinary tract infection that has not resolved prior to randomization

          -  Surgical treatment for stress urinary incontinence or pelvic organ prolapse
             recommended or planned at time of enrollment

          -  Surgically altered detrusor muscle

          -  Known diagnosis or history of neurogenic bladder, post void residual volume &gt;150ml,
             bladder malignancy, interstitial cystitis/painful bladder syndrome, or pelvic
             radiation

          -  Surgery for pelvic organ prolapse or stress urinary incontinence within the previous
             3 months

          -  Pregnancy, lactation, or planned pregnancy during study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nazema Y Siddiqui, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Urogynecology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke OB/GYN Consultants of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>June 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Urge Incontinence</keyword>
  <keyword>Posterior Tibial Nerve Stimulation</keyword>
  <keyword>PTNS</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Oxybutynin</keyword>
  <keyword>Anticholinergic Medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
